JT to Cease Development of Osteoporosis Treatment following Termination of License Agreement with Merck

October 19, 2011
Japan Tobacco (JT) announced on October 17 that the company will cease the development of its osteoporosis treatment JTT-305. The decision was made after due consideration of the results of clinical trials both in Japan and overseas following the receipt...read more